Table 2.
Clinical Trials Involving SARS-CoV-2 Vaccines
| NCT number | Vaccine type | Sponsor/collaborators | Trial phase | Location |
|---|---|---|---|---|
| NCT04299724 | Artificial APCs expressing SARS-CoV-2 proteins | Shenzhen Geno-Immune Medical Institute | 1 | Guangdong, China |
| NCT04383574 | Alum-adjuvanted, formalin-inactivated vaccine | Sinovac Research and Development Co, Ltd | 1/2 | Hebei, China |
| NCT04352608 | Alum-adjuvanted, formalin-inactivated vaccine | Sinovac Research and Development Co, Ltd | 1/2 | Jiangsu, China |
| NCT04450004 | Virus-like particle vaccine | Medicago Inc | 1 | Not provided |
| NCT04412538 | Inactivated SARS-CoV-2 vaccine | Chinese Academy of Medical Sciences, West China Second University Hospital, Yunnan Center for Disease Control and Prevention | 1/2 | Sichuan, China |
| NCT04283461 | RNA vaccine: mRNA-1273 | National Institute of Allergy and Infectious Diseases | 1 | United States |
| NCT04405908 | Subunit vaccine: spike protein trimer | Clover Biopharmaceuticals AUS Pty Ltd | 1 | Australia |
| NCT04313127 | Vectored vaccine: adenovirus type 5 vector | CanSino Biologics Inc, Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China, Jiangsu Provincial Center for Disease Control and Prevention, Hubei Provincial Center for Disease Control and Prevention, Tongji Hospital | 1 | Hubei, China |
| NCT04437875 | Vectored vaccine: adenovirus type 26 with spike protein | Gamaleya Research Institute of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Acellena Contract Drug Research and Development | 1/2 | Russia |
| NCT04368728 | RNA vaccines: BNT162a1, BNT162b1, BNT162b2, BNT162c2 | BioNTech SE, Pfizer Inc | 1/2 | United States |
| NCT04341389 | Vectored vaccine: adenovirus type 5 vector | Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China, CanSino Biologics Inc, Jiangsu Provincial Center for Disease Control and Prevention, Hubei Provincial Center for Disease Control and Prevention, Zhongnan Hospital | 2 | Hubei, China |
| NCT04386252 | Artificial APCs expressing SARS-CoV-2 proteins | AIVITA Biomedical, Inc | 1/2 | United States |
| NCT04368988 | Nanoparticle vaccine with Matrix-M adjuvant | Novavax, Inc | 1 | Australia |
| NCT04324606 | Vectored vaccine: chimpanzee adenovirus, ChAdOx1 | University of Oxford | 1/2 | United Kingdom |
| NCT04334980 | Oral vaccine: bacTRL-Spike | Symvivo Corporation | 1 | United States, Canada |
| NCT04405076 | RNA vaccine: mRNA-1273 | Moderna, Inc, Biomedical Advanced Research and Development Authority | 2 | United States |
| NCT04400838 | Vectored vaccine: chimpanzee adenovirus, ChAdOx1 | University of Oxford | 2/3 | United Kingdom |
| NCT04428073 | Vectored vaccine: adeno-associated virus | GeneCure Biotechnologies | 1 | Not provided |
| NCT04453852 | Recombinant protein vaccine with Advax-SM adjuvant | Vaxine Pty Ltd, Central Adelaide Local Health Network Incorporated | 1 | Australia |
| NCT04398147 | Vectored vaccine: adenovirus type 5 vector | CanSino Biologics Inc, Beijing Institute of Biotechnology, Canadian Center for Vaccinology | 1/2 | Canada |
| NCT04444674 | Vectored vaccine: chimpanzee adenovirus, ChAdOx1 | University of Witwatersrand, South Africa, South African Medical Research Council, Bill and Melinda Gates Foundation, University of Oxford | 1/2 | South Africa |
| NCT04449276 | Biological: CVnCoV vaccine; Drug: placebo | CureVac AG, Coalition for Epidemic Preparedness Innovations | 1 | Germany |
| NCT04447781 | DNA vaccine: INO-4800 | International Vaccine Institute, Coalition for Epidemic Preparedness Innovations, INOVIO Pharmaceuticals | 1/2 | Not provided |
| NCT04336410 | DNA vaccine: INO-4800 | INOVIO Pharmaceuticals, Coalition for Epidemic Preparedness Innovations | 1 | United States |
| NCT04380701 | RNA vaccines: BNT162a1, BNT162b1, BNT162b2, BNT162c2 | BioNTech RNA Pharmaceuticals GmbH, BioNTech SE | 1/2 | Germany |
APCs = antigen-presenting cells; NCT = National Clinical Trial; PLA = People’s Liberation Army; SARS-CoV-2 = severe acute respiratory syndrome coronavirus.